文献速递眼底病与葡萄膜炎

阻断膜联蛋白A2可预防糖尿病视网膜病变小鼠模型的早期微血管病变

Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

研究在糖尿病Akita小鼠和氧诱导视网膜病变(OIR)小鼠中测试Anxa2基因敲除及玻璃体腔注射抗A2抗体对周细胞丢失和视网膜新生血管的影响。结果显示基因敲除和免疫阻断A2均防止糖尿病小鼠视网膜周细胞耗竭,抗A2还减少OIR模型的血管闭塞和新生血管,联合抗VEGF效果增强。作者认为靶向A2单用或联合抗VEGF在小鼠中有效,可能减缓人类糖尿病视网膜血管病变进展。

要点

  • Anxa2基因敲除和抗A2抗体均防止糖尿病Ins2AKITA小鼠视网膜周细胞耗竭。
  • 抗A2抗体减少OIR模型血管闭塞和新生血管,联合抗VEGF时效果增强。
  • 作者认为靶向A2单用或联合抗VEGF在小鼠中有效,可能减缓人类糖尿病视网膜血管病变进展。

核心结论

  • 靶向A2的治疗方法单用或联合抗VEGF治疗在小鼠中有效,可能减缓人类糖尿病视网膜血管病变的进展。

研究设计与样本

  • 分析伴或不伴Anxa2全局敲除的糖尿病Ins2AKITA小鼠,以及2、4、6月龄接受玻璃体腔抗A2 IgG或对照抗体的Ins2AKITA小鼠,7月龄时评估视网膜周细胞丢失。
  • 在新生小鼠OIR模型中评估玻璃体腔抗A2对视网膜新生血管面积、血管闭塞面积和新生血管簇计数的影响。

主要发现

  • Anxa2基因敲除和A2免疫阻断均防止糖尿病Ins2AKITA小鼠视网膜周细胞耗竭。
  • 阻断A2减少OIR模型中血管闭塞和新生血管。
  • 联合使用抗VEGF和抗A2抗体时该效果增强。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We examined the role of annexin A2 (A2) in the development of diabetic retinal vasculopathy by testing the effect of Anxa2 gene deletion as well as administration of anti-A2 antibodies on pericyte dropout and retinal neovascularization in diabetic Akita mice, and in mice subjected to oxygen-induced retinopathy. METHODS: We analyzed diabetic Ins2AKITA mice with or without global deletion of Anxa2, as well as Ins2AKITA mice that received intravitreal anti-A2 IgG or control antibody at 2, 4, and 6 months, for retinal pericyte dropout at 7 months of age. In addition, we assessed the effect of intravitreal anti-A2 on oxygen-induced retinopathy (OIR) in neonatal mice by quantifying retinal neovascular and vaso-obliterative area, and by enumeration of neovascular tufts. RESULTS: Both deletion of the Anxa2 gene and immunologic blockade of A2 prevented pericyte depletion in retinas of diabetic Ins2AKITA mice. Blockade of A2 also reduced vaso-obliteration and neovascularization in the OIR model of vascular proliferation. This effect was amplified when a combination of antivascular endothelial growth factor (VEGF) and anti-A2 antibodies was used. CONCLUSIONS: Therapeutic approaches that target A2, alone or in combination with anti-VEGF therapy, are effective in mice, and may also curtail the progression of retinal vascular disease in humans with diabetes.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Dallacasagrande V, Liu W, Almeida D, et al. Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2023. PMID: 37103008. doi:10.1167/iovs.64.4.33

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。